PEDIATRIC ONCOLOGY GROUP

儿科肿瘤学小组(POG)是一个多机构、 以控制癌症为目标的多学科合作小组 儿童和青少年的治疗研究旨在改善 生存和生活质量。101家机构和1,906名个人 POG成员汇集他们的知识和资源，共同开发和 进行各种大规模的临床和实验室研究。 成员调查人员包括儿科肿瘤学家、病理学家、 外科医生，放射治疗师，诊断放射科医生，统计学家， 临床研究助理、肿瘤学护士专家和其他 合作改善治疗结果，更好地理解 儿童癌症生物学。参考实验室进行了一系列 遗传学、分子和细胞学生物样本的辅助研究 生物特征与后续生物学特征的相关性 患者特征和结果，提供独特的机会 解决与风险评估、流行病学、 病理生物学和其他与癌症相关的话题。 这份五年续期申请的总体目标是增加 所有形式的儿童癌症的治愈率同时降低 基于风险的设计治疗的急性和远期后果 治疗。我们的目标还包括增加应计利润，减少 招生，提高长期跟踪，延长福利 参与临床试验。传统的结果分析和 翻译研究将得到创新研究的补充 替代终端，包括成本和生活质量。 运营办公室是集团的中央总部，提供 为整体科学、行政和财政提供工作人员和支持 本集团的管理。行动办公室的职能包括 负责与NCI的所有互动，审查个人和 本集团的机构成员地位和业绩、维持 书目，召集和执行半年一次的职责 会议、分发每月邮件和会议纪要、监督 质量控制和机构审计、筹备责任 协调所有协议，从概念/LOI到激活和 必要时的修订和修正，并提供后勤和 对科学委员会的财政支持，并支付三分之一 在没有合作的情况下与参与者相关的当事人付款 来自NCI的协议。在一般科学监督的所有方面和 为所研究的每种疾病制定研究计划和分析， 业务处与统计局密切合作，无缝合作 协调努力。 此应用程序请求续订并继续终止运营 办公室以及科学委员会、参考实验室和 本集团的人员。

The Pediatric Oncology Group (POG) is a multi-institutional, multidisciplinary cooperative Group whose goal is to control cancer among children and adolescents by therapeutic research aimed at improving the survival and quality of life. The 101 institutions and 1,906 individual members of POG pool their knowledge and resources to jointly develop and conduct a wide variety of large-scale clinical and laboratory studies. Member investigators include pediatric oncologists, pathologists, surgeons, radiation therapists, diagnostic radiologists, statisticians, clinical research assistants, oncology nurse specialists, and others who cooperate to improve the outcomes of treatment and better understand the biology of childhood cancer. Reference laboratories conduct an array of adjunct studies of biologic samples for genetic, molecular, and cellular characteristics with subsequent correlation of biologic features with patient characteristics and outcome, providing unique opportunities to address scientific questions relating to risk assessment, epidemiology, pathobiology and other cancer-related topics. The overall aims of this five-year renewal application are to increase cure rates of all forms of childhood cancer while simultaneously reducing the acute and late consequences of treatment by design of risk-based therapies. We also aim to increase accruals, reduce barriers to enrollment, improve long-term follow-up, and extend the benefits of clinical trials participation. Traditional outcome analyses and translational research will be supplemented by innovative studies of alternative endpoints, including costs and quality of life. The Operations Office is the central Group headquarters and provides the staff and support for the overall scientific, administrative, and fiscal management of the Group. The Operations Office functions include responsibilities for all interactions with NCI, review of individual and institutional membership status and performance, maintenance of the Group bibliography, responsibility for convening and conducting semiannual meetings, distribution of monthly mailings and minutes, oversight of quality control and institutional audits, responsibility for preparation and coordination of all protocols from concept/LOI through activation and revisions and amendments as necessary, and provision of logistical and financial support to scientific committees, and disbursement of third party payments where relevant for participants without cooperative agreements from NCI. In all aspects of general scientific oversight and development of research plans and analyses for each disease studied, the Operations Office works closely with the Statistical Office in a seamless coordination of effort. This application requests renewed and continued ending for the Operations Office and for the scientific committees, reference laboratories and key personnel of the Group.